The 12 most recent market catalysts affecting $CYTK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Joseph Pantginis has reaffirmed a 'Buy' rating and a $140 price target for Cytokinetics (CYTK). This is a routine analyst…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Cytokinetics Says New Trial Data Strengthens Case For Aficamten Across Heart Condition Types
Cytokinetics released additional positive data from its ACACIA-HCM and MAPLE-HCM trials for aficamten, presented at the ESC Congress 2026 and published in leading medical journals.…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 85
Cytokinetics shares are trading lower. The company reported pivotal Phase 3 ACACIA‑HCM results showing aficamten met both dual primary endpoints, with significant improvements in patient quality‑of‑life scores and exercise capacity versus placebo.
The headline presents a classic 'sell the news' scenario where a company's stock declines despite positive clinical trial results. This often occurs when the market has already lar…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 85
Cytokinetics Announces Primary Results From Phase 3 Trial Of Aficamten In Non-Obstructive Hypertrophic Cardiomyopathy To Be Presented August 28 At ESC Congress
The upcoming presentation of Phase 3 trial results for Aficamten is a critical binary event for Cytokinetics. Positive data could unlock significant value, leading to potential FDA…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110
Barclays analyst Emily Field has maintained an 'Overweight' rating on Cytokinetics and raised the price target from $95 to $110. This action signals a strengthened positive outlook…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103
JP Morgan analyst Tessa Romero has maintained an 'Overweight' rating on Cytokinetics (CYTK) and raised the price target from $97 to $103. This move indicates a strengthened positiv…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112
Truist Securities analyst Srikripa Devarakonda maintained a 'Buy' rating on Cytokinetics and raised the price target from $106 to $112. This action signals increased confidence fro…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112
RBC Capital analyst Leonid Timashev maintained an 'Outperform' rating for Cytokinetics (CYTK) but adjusted the price target downwards from $117 to $112. This action signals that wh…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110
Citizens analyst Jason N. Butler has reiterated a 'Market Outperform' rating for Cytokinetics and raised the price target from $105 to $110. This action signals continued bullish s…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Cytokinetics, Raises Price Target to $112
Needham analyst Serge Belanger maintained a 'Buy' rating on Cytokinetics (CYTK) and raised the price target from $102 to $112. This action signals an analyst's increased conviction…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M Estimate
Cytokinetics (CYTK) reported Q2 earnings with a loss of $(1.50) per share, beating the analyst consensus of $(1.63). This 7.98% beat on EPS, coupled with sales of $28.624 million w…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients
Cytokinetics announced that its drug, MYQORZO (aficamten), has received marketing authorization in the UK and positive guidance from NICE for treating symptomatic oHCM. This is a s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.